Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Merit Ester Cudkowicz, M.D.

Co-Author

This page shows the publications co-authored by Merit Cudkowicz and Nazem Atassi.
Connection Strength

4.778
  1. Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology. 2013 Oct 08; 81(15):1350-5.
    View in: PubMed
    Score: 0.564
  2. Depression in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011 Mar; 12(2):109-12.
    View in: PubMed
    Score: 0.465
  3. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial. Neuroimage Clin. 2021; 30:102672.
    View in: PubMed
    Score: 0.239
  4. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021 Feb 01; 78(2):186-196.
    View in: PubMed
    Score: 0.236
  5. Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020 02; 21(1-2):15-23.
    View in: PubMed
    Score: 0.215
  6. A pilot trial of RNS60 in amyotrophic lateral sclerosis. Muscle Nerve. 2019 03; 59(3):303-308.
    View in: PubMed
    Score: 0.204
  7. Imaging of glia activation in people with primary lateral sclerosis. Neuroimage Clin. 2018; 17:347-353.
    View in: PubMed
    Score: 0.188
  8. Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS). J Neurol Neurophysiol. 2017 Apr; 8(2).
    View in: PubMed
    Score: 0.182
  9. Analysis of Participant Withdrawal in Huntington Disease Clinical Trials. J Huntingtons Dis. 2017; 6(2):149-156.
    View in: PubMed
    Score: 0.178
  10. Analysis of Participant Withdrawal in Huntington Disease Clinical Trials. J Huntingtons Dis. 2017; 6(4):371.
    View in: PubMed
    Score: 0.178
  11. Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis. Neurology. 2016 Dec 13; 87(24):2554-2561.
    View in: PubMed
    Score: 0.176
  12. Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population. J Clin Neuromuscul Dis. 2016 Mar; 17(3):99-105.
    View in: PubMed
    Score: 0.168
  13. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015; 7:409-14.
    View in: PubMed
    Score: 0.155
  14. Disease burden in upper motor neuron syndromes: a survey of patient perspectives. J Clin Neuromuscul Dis. 2014 Dec; 16(2):104-5.
    View in: PubMed
    Score: 0.154
  15. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov 04; 83(19):1719-25.
    View in: PubMed
    Score: 0.152
  16. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep; 15(5-6):453-6.
    View in: PubMed
    Score: 0.149
  17. 7-T MRI of the spinal cord can detect lateral corticospinal tract abnormality in amyotrophic lateral sclerosis. Muscle Nerve. 2013 May; 47(5):760-2.
    View in: PubMed
    Score: 0.137
  18. Advanced statistical methods to study the effects of gastric tube and non-invasive ventilation on functional decline and survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011 Jul; 12(4):272-7.
    View in: PubMed
    Score: 0.120
  19. A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 Dec; 11(6):508-13.
    View in: PubMed
    Score: 0.114
  20. Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients. Muscle Nerve. 2021 09; 64(3):309-320.
    View in: PubMed
    Score: 0.061
  21. Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle Nerve. 2021 03; 63(3):371-383.
    View in: PubMed
    Score: 0.059
  22. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020 07 09; 383(2):109-119.
    View in: PubMed
    Score: 0.057
  23. Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology. 2019 10 22; 93(17):e1605-e1617.
    View in: PubMed
    Score: 0.054
  24. ALS/SURV: a modification of the CAFS statistic. Amyotroph Lateral Scler Frontotemporal Degener. 2019 11; 20(7-8):576-583.
    View in: PubMed
    Score: 0.053
  25. Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach. Sci Rep. 2019 01 24; 9(1):690.
    View in: PubMed
    Score: 0.051
  26. Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Ann Clin Transl Neurol. 2018 Jun; 5(6):730-740.
    View in: PubMed
    Score: 0.049
  27. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018 02 13; 90(7):e565-e574.
    View in: PubMed
    Score: 0.048
  28. A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):250-258.
    View in: PubMed
    Score: 0.047
  29. Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open-Access ALS clinical trials database. Muscle Nerve. 2018 03; 57(3):430-434.
    View in: PubMed
    Score: 0.047
  30. Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials. Neurology. 2016 Jul 26; 87(4):392-400.
    View in: PubMed
    Score: 0.043
  31. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry. 2017 Feb; 88(2):99-105.
    View in: PubMed
    Score: 0.043
  32. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. Neurology. 2016 Apr 19; 86(16):1474-81.
    View in: PubMed
    Score: 0.042
  33. Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Muscle Nerve. 2015 Sep; 52(3):339-43.
    View in: PubMed
    Score: 0.040
  34. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm. 2015 Jun; 2(3):e100.
    View in: PubMed
    Score: 0.039
  35. Neuroprotective agents target molecular mechanisms of disease in ALS. Drug Discov Today. 2015 Jan; 20(1):65-75.
    View in: PubMed
    Score: 0.038
  36. Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec; 14(7-8):632-4.
    View in: PubMed
    Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.